Biotech’s Big Slowdown

The biotech industry’s recent misfortunes have made valuations more reasonable making a way for improved performance.  Recent reports show that biotech firms – firms that develop drugs from living cells versus chemicals – tend to grow at a faster rate than big pharma – but their pace has been slowing down.

In recent news, several major acquisitions completed last year help the pharma growth profile yet valuations between biotech and big pharma are coming more in line.  New clinical data coming out this year could again help biotech growth and encourage investors.

Read More